Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies.
Afsane BahramiMajid KhazaeiFariba BagheriehMajid Ghayour-MobarhanMina MaftouhSeyed Mahdi HassanianSoodabeh ShahidsalesPublished in: Journal of cellular physiology (2017)
Desmoplasia or abundant fibrotic stroma is a typical property of most malignancies, which has a great effect on tumorigenesis, angiogenesis, and resistance to therapy. The activated stroma cells comprises several cell types including endothelial cells, nerve cells, inflammatory/macrophages cells, stellate cells, and extracellular matrix. In other word, the interactions of cancer-stroma modulate tumorigenesis, therapy resistance, and poor delivery of drugs. Therefore, targeting the tumor stroma in combination with conventional chemotherapeutic agents could provide a promising approach in the treatment of pancreatic cancer. This review summarizes the current knowledge about pancreatic stellate cells, targeting stroma compartments with particular emphasis on preclinical, and clinical trials on targeting of stroma as an option in pancreatic cancer treatment.
Keyphrases
- induced apoptosis
- cell cycle arrest
- endothelial cells
- clinical trial
- extracellular matrix
- healthcare
- endoplasmic reticulum stress
- stem cells
- drug delivery
- randomized controlled trial
- squamous cell carcinoma
- cell therapy
- single cell
- cell proliferation
- young adults
- cell death
- idiopathic pulmonary fibrosis
- papillary thyroid
- pi k akt
- open label
- study protocol
- replacement therapy
- phase ii
- phase iii